

MUFG Bank, Ltd.

A member of MUFG, a global financial group

MUFG to Invest in Orizuru Therapeutics Inc.

Tokyo, August 10, 2021 --- MUFG Bank today announced that it has decided to invest in Orizuru Therapeutics Inc. (“OZTx”), with the main objectives of contributing to the development of next generation industries and enhancing the Japanese economy’s global competitiveness.

In 2015, the Center for iPS Cell Research and Application (“CiRA”)¹ and Takeda Pharmaceutical Company Limited (“Takeda Pharmaceutical”) agreed to launch a joint research program, called T-CiRA², to accelerate research for practical application of iPS cell technology in drug development, and to deliver that technology to society in the form of regenerative medicine. Following the recent validation of pre-clinical efficacy of iPS therapy projects, on April 1, 2021 OZTx was founded through collaboration between Kyoto University Innovation Capital Limited³ and Takeda Pharmaceutical. OZTx started operation on June 1, 2021 as a research and development-driven company focusing on the development of iPS cell-based regenerative medicine and the application of iPS cell technology. To deliver cell therapies to patients, OZTx promotes the wide use of cell therapy products and innovative iPS cell-related technologies as it seeks to contribute to society and patients by delivering regenerative medicine using iPS cells, developed in Japan. OZTx has a vision of offering the hope to the world that, by leveraging the power of science, better health is on the horizon.

In recent years the field of life science has become important for addressing Japan’s aging population and low birth rate and the realization of a long-living society. Through this investment in OZTx, Mitsubishi UFJ Financial Group, Inc. (MUFG) will leverage its domestic and overseas networks to support iPS cell technologies’ application, commercialization and business incubation.

As MUFG directs our efforts to achieving sustainability for the environment and society, we have reviewed our priority issues in view of our newly defined purpose, “Committed to empowering a brighter future.” Considering both societal expectations and affinities with MUFG’s business areas, we have identified 10 priority issues. Of these priority issues, support for business incubation in the field of life science through this investment falls under the issues of “Supporting industrial development and innovation” and “Overcoming threats to health.”

¹ The Center for iPS Cell Research and Application (“CiRA”)

<https://www.cira.kyoto-u.ac.jp/e/index.html>

² T-CiRA

<https://www.takeda.com/what-we-do/t-cira/>

³ Kyoto University Innovation Capital Limited (KYOTO-iCAP)

<https://www.kyoto-unicap.co.jp/en/>

MUFG will continue to provide stable support to venture companies, which will play a role in next-generation industries, towards the resolution of medium- to long-term environmental and social issues and to support customers' sustainable growth.

Details

| | |
|----------------------|---|
| Registered name | Orizuru Therapeutics Inc. |
| Business description | <ol style="list-style-type: none"> 1. Development of regenerative medicine products through cell transplantation 2. Support for drug discovery research and development of regenerative medicine research infrastructure using iPS cell-related technology |
| Investors | Kyoto University Innovation Capital Co., Ltd., Takeda Pharmaceutical Company Limited, MUFG Bank, Ltd., SMBC Venture Capital Co., Ltd., MEDIPAL HOLDINGS CORPORATION, Sumitomo Mitsui Finance and Leasing Company Co. Ltd., Sumitomo Mitsui Trust Bank, Limited, Nippon Venture Capital (NVCC) |
| For more details | Visit https://www.orizuru-therapeutics.com/ |

- End -

About MUFG Bank

MUFG Bank, Ltd. is Japan's premier bank, with a global network spanning around 50 countries. Outside of Japan, the bank offers an extensive scope of commercial and investment banking products and services to businesses, governments and individuals worldwide.

MUFG Bank's parent, Mitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world's leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,500 locations in more than 50 countries. The Group has about 170,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to "be the world's most trusted financial group" through close collaboration among our operating companies and flexibly respond to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG's shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit <https://www.mufg.jp/english>.